Lu Huang
Concepts (168)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mycobacterium tuberculosis | 14 | 2024 | 285 | 4.750 |
Why?
| Eosinophils | 4 | 2016 | 39 | 2.010 |
Why?
| Tuberculosis | 8 | 2024 | 146 | 1.980 |
Why?
| Macrophages | 11 | 2022 | 363 | 1.630 |
Why?
| Macrophages, Alveolar | 3 | 2022 | 28 | 1.610 |
Why?
| Trichinellosis | 4 | 2017 | 5 | 1.560 |
Why?
| Host-Pathogen Interactions | 11 | 2024 | 134 | 1.420 |
Why?
| Lung | 8 | 2024 | 486 | 1.340 |
Why?
| Tuberculosis, Pulmonary | 5 | 2024 | 107 | 1.300 |
Why?
| Trichinella spiralis | 4 | 2017 | 4 | 1.160 |
Why?
| Host-Parasite Interactions | 2 | 2016 | 16 | 1.090 |
Why?
| Neutrophil Activation | 1 | 2024 | 14 | 0.960 |
Why?
| Antitubercular Agents | 4 | 2021 | 106 | 0.890 |
Why?
| Neutrophils | 1 | 2024 | 145 | 0.870 |
Why?
| Animals | 29 | 2024 | 13187 | 0.840 |
Why?
| Protein-Tyrosine Kinases | 2 | 2020 | 95 | 0.820 |
Why?
| Bacterial Infections | 1 | 2022 | 95 | 0.780 |
Why?
| Mice | 20 | 2024 | 5739 | 0.780 |
Why?
| Mice, Inbred C57BL | 14 | 2024 | 1816 | 0.740 |
Why?
| Immunity, Innate | 2 | 2017 | 104 | 0.680 |
Why?
| Leishmaniasis, Cutaneous | 3 | 2015 | 14 | 0.670 |
Why?
| Respiratory Tract Infections | 1 | 2020 | 75 | 0.660 |
Why?
| Eosinophilia | 2 | 2016 | 37 | 0.640 |
Why?
| Tissue Culture Techniques | 1 | 2018 | 40 | 0.640 |
Why?
| High-Throughput Screening Assays | 1 | 2018 | 37 | 0.630 |
Why?
| Granuloma | 1 | 2018 | 43 | 0.620 |
Why?
| Drug Evaluation, Preclinical | 1 | 2018 | 144 | 0.610 |
Why?
| Interleukin-4 | 3 | 2018 | 43 | 0.610 |
Why?
| Tuberculosis Vaccines | 1 | 2017 | 2 | 0.600 |
Why?
| T-Lymphocytes | 1 | 2020 | 338 | 0.590 |
Why?
| Helminthiasis | 1 | 2016 | 2 | 0.550 |
Why?
| Interleukin-10 | 3 | 2024 | 84 | 0.550 |
Why?
| Immunotherapy | 1 | 2017 | 238 | 0.510 |
Why?
| Toll-Like Receptor 2 | 1 | 2015 | 24 | 0.500 |
Why?
| Larva | 1 | 2014 | 26 | 0.500 |
Why?
| Lipopeptides | 1 | 2015 | 63 | 0.490 |
Why?
| Nitric Oxide | 2 | 2014 | 253 | 0.440 |
Why?
| Interferon-gamma | 4 | 2024 | 177 | 0.420 |
Why?
| Mice, Knockout | 5 | 2024 | 841 | 0.390 |
Why?
| Ovary | 2 | 2021 | 104 | 0.360 |
Why?
| Phagocytes | 2 | 2019 | 12 | 0.320 |
Why?
| Disease Models, Animal | 4 | 2024 | 1455 | 0.320 |
Why?
| CD4-Positive T-Lymphocytes | 2 | 2024 | 164 | 0.310 |
Why?
| Fatty Acids | 2 | 2019 | 146 | 0.300 |
Why?
| Monocytes | 2 | 2018 | 131 | 0.300 |
Why?
| Hypertension | 2 | 2024 | 533 | 0.300 |
Why?
| Transcription, Genetic | 3 | 2018 | 369 | 0.300 |
Why?
| CD8-Positive T-Lymphocytes | 2 | 2024 | 116 | 0.260 |
Why?
| Dendritic Cells | 3 | 2015 | 133 | 0.250 |
Why?
| Immunity | 2 | 2022 | 35 | 0.250 |
Why?
| Rats | 3 | 2015 | 3305 | 0.240 |
Why?
| Cytokines | 2 | 2019 | 612 | 0.230 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2024 | 40 | 0.230 |
Why?
| Homeodomain Proteins | 1 | 2024 | 80 | 0.220 |
Why?
| Chlamydia muridarum | 1 | 2024 | 41 | 0.220 |
Why?
| Sequence Analysis, RNA | 2 | 2021 | 91 | 0.220 |
Why?
| Cell Proliferation | 3 | 2018 | 1007 | 0.220 |
Why?
| Chlamydia Infections | 1 | 2024 | 77 | 0.220 |
Why?
| Receptors, Antigen, T-Cell | 2 | 2020 | 51 | 0.210 |
Why?
| Humans | 12 | 2024 | 49974 | 0.210 |
Why?
| Th1 Cells | 2 | 2024 | 52 | 0.200 |
Why?
| Interleukin-17 | 2 | 2020 | 36 | 0.200 |
Why?
| Luminescent Proteins | 1 | 2021 | 53 | 0.190 |
Why?
| Mitochondria | 1 | 2024 | 402 | 0.190 |
Why?
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2020 | 4 | 0.180 |
Why?
| Isoniazid | 2 | 2018 | 37 | 0.180 |
Why?
| Rifampin | 2 | 2018 | 62 | 0.170 |
Why?
| Metabolism | 1 | 2019 | 25 | 0.170 |
Why?
| Microbial Viability | 1 | 2019 | 30 | 0.170 |
Why?
| Phagosomes | 1 | 2019 | 19 | 0.170 |
Why?
| Vacuoles | 1 | 2019 | 22 | 0.170 |
Why?
| Cells, Cultured | 2 | 2020 | 1573 | 0.170 |
Why?
| Gene Expression Regulation, Bacterial | 2 | 2021 | 191 | 0.160 |
Why?
| Granuloma, Respiratory Tract | 1 | 2018 | 1 | 0.160 |
Why?
| Matrix Metalloproteinase Inhibitors | 1 | 2018 | 10 | 0.160 |
Why?
| Aging | 2 | 2021 | 687 | 0.160 |
Why?
| Genes, Reporter | 1 | 2018 | 89 | 0.150 |
Why?
| Bystander Effect | 1 | 2018 | 26 | 0.150 |
Why?
| Small Molecule Libraries | 1 | 2018 | 68 | 0.150 |
Why?
| Glycolysis | 1 | 2018 | 70 | 0.150 |
Why?
| Metabolic Networks and Pathways | 1 | 2018 | 89 | 0.150 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 244 | 0.150 |
Why?
| T-Box Domain Proteins | 1 | 2017 | 14 | 0.150 |
Why?
| Immunomodulation | 1 | 2017 | 37 | 0.150 |
Why?
| Cell Cycle | 1 | 2018 | 231 | 0.140 |
Why?
| Oxidation-Reduction | 1 | 2018 | 322 | 0.140 |
Why?
| Mice, Inbred BALB C | 2 | 2015 | 304 | 0.140 |
Why?
| Drug Resistance, Bacterial | 1 | 2016 | 71 | 0.130 |
Why?
| Signal Transduction | 2 | 2020 | 1618 | 0.130 |
Why?
| Influenza A Virus, H3N8 Subtype | 1 | 2015 | 1 | 0.130 |
Why?
| Bacterial Proteins | 1 | 2019 | 376 | 0.130 |
Why?
| RNA, Messenger | 1 | 2018 | 1105 | 0.130 |
Why?
| Injections | 1 | 2015 | 55 | 0.130 |
Why?
| Eosinophil Major Basic Protein | 1 | 2014 | 1 | 0.130 |
Why?
| Eosinophil Peroxidase | 1 | 2014 | 1 | 0.130 |
Why?
| Antibodies, Helminth | 1 | 2014 | 4 | 0.130 |
Why?
| Immunization, Passive | 1 | 2014 | 29 | 0.120 |
Why?
| Trachea | 1 | 2015 | 52 | 0.120 |
Why?
| Leukocyte Count | 1 | 2014 | 70 | 0.120 |
Why?
| Models, Biological | 1 | 2018 | 727 | 0.120 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2014 | 66 | 0.120 |
Why?
| Arginase | 1 | 2014 | 35 | 0.120 |
Why?
| Coinfection | 1 | 2014 | 38 | 0.120 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 411 | 0.120 |
Why?
| Genetic Variation | 1 | 2015 | 213 | 0.120 |
Why?
| Plasma Cells | 1 | 2014 | 223 | 0.110 |
Why?
| Anti-Bacterial Agents | 1 | 2019 | 744 | 0.110 |
Why?
| Sodium Chloride, Dietary | 2 | 2024 | 33 | 0.110 |
Why?
| Immunohistochemistry | 1 | 2015 | 973 | 0.110 |
Why?
| Sodium | 2 | 2024 | 92 | 0.110 |
Why?
| Chronic Disease | 1 | 2014 | 567 | 0.100 |
Why?
| Leishmaniasis Vaccines | 1 | 2010 | 1 | 0.090 |
Why?
| Leishmania major | 1 | 2010 | 9 | 0.090 |
Why?
| T-Lymphocytes, Helper-Inducer | 1 | 2010 | 42 | 0.090 |
Why?
| Pyrazinamide | 1 | 2009 | 7 | 0.090 |
Why?
| Antiprotozoal Agents | 1 | 2009 | 9 | 0.090 |
Why?
| Muscle, Skeletal | 1 | 2014 | 750 | 0.080 |
Why?
| Vaccination | 1 | 2010 | 266 | 0.080 |
Why?
| Female | 4 | 2024 | 26472 | 0.080 |
Why?
| Cell Line | 3 | 2016 | 1000 | 0.070 |
Why?
| Receptors, Purinergic P2X7 | 1 | 2024 | 7 | 0.060 |
Why?
| Adenosine Triphosphate | 1 | 2024 | 233 | 0.050 |
Why?
| Sodium Chloride Symporters | 1 | 2022 | 7 | 0.050 |
Why?
| Kidney Tubules, Distal | 1 | 2022 | 14 | 0.050 |
Why?
| Heme | 1 | 2021 | 21 | 0.050 |
Why?
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 39 | 0.050 |
Why?
| Ovulation | 1 | 2021 | 4 | 0.050 |
Why?
| Single-Cell Analysis | 1 | 2021 | 57 | 0.050 |
Why?
| Cell Differentiation | 1 | 2024 | 651 | 0.050 |
Why?
| Gene Expression Regulation | 2 | 2020 | 976 | 0.050 |
Why?
| Microscopy, Confocal | 1 | 2021 | 88 | 0.050 |
Why?
| Male | 1 | 2020 | 25241 | 0.040 |
Why?
| RNA | 1 | 2020 | 170 | 0.040 |
Why?
| Base Sequence | 1 | 2020 | 643 | 0.040 |
Why?
| Chemokine CCL3 | 1 | 2018 | 8 | 0.040 |
Why?
| Mutant Proteins | 1 | 2019 | 37 | 0.040 |
Why?
| Macrophage Activation | 1 | 2018 | 25 | 0.040 |
Why?
| Chemokine CCL2 | 1 | 2018 | 70 | 0.040 |
Why?
| Transcriptome | 1 | 2020 | 315 | 0.040 |
Why?
| HeLa Cells | 1 | 2018 | 250 | 0.040 |
Why?
| Flow Cytometry | 1 | 2021 | 476 | 0.040 |
Why?
| Epigenesis, Genetic | 1 | 2021 | 374 | 0.040 |
Why?
| Lymphocytes | 1 | 2018 | 152 | 0.040 |
Why?
| Thymocytes | 1 | 2017 | 2 | 0.040 |
Why?
| Th2 Cells | 1 | 2017 | 21 | 0.040 |
Why?
| Ovarian Neoplasms | 1 | 2021 | 447 | 0.040 |
Why?
| Myeloid Cells | 1 | 2016 | 38 | 0.030 |
Why?
| Gene Expression Profiling | 1 | 2020 | 1032 | 0.030 |
Why?
| Sialic Acids | 1 | 2015 | 2 | 0.030 |
Why?
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2015 | 2 | 0.030 |
Why?
| Virus Attachment | 1 | 2015 | 3 | 0.030 |
Why?
| Viral Tropism | 1 | 2015 | 5 | 0.030 |
Why?
| Adaptation, Biological | 1 | 2015 | 10 | 0.030 |
Why?
| Receptors, Virus | 1 | 2015 | 24 | 0.030 |
Why?
| Horses | 1 | 2015 | 44 | 0.030 |
Why?
| Dogs | 1 | 2015 | 182 | 0.030 |
Why?
| Phylogeny | 1 | 2015 | 235 | 0.030 |
Why?
| Protein Binding | 1 | 2015 | 660 | 0.030 |
Why?
| Antibodies, Blocking | 1 | 2010 | 8 | 0.020 |
Why?
| Oligodeoxyribonucleotides | 1 | 2010 | 29 | 0.020 |
Why?
| CpG Islands | 1 | 2010 | 108 | 0.020 |
Why?
| Lymphocyte Activation | 1 | 2010 | 172 | 0.020 |
Why?
| Interleukin-12 | 1 | 2009 | 31 | 0.020 |
Why?
| Mutation | 1 | 2015 | 1294 | 0.020 |
Why?
| Interleukin-6 | 1 | 2010 | 264 | 0.020 |
Why?
| Cell Survival | 1 | 2009 | 600 | 0.020 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2009 | 388 | 0.020 |
Why?
| Skin | 1 | 2010 | 409 | 0.020 |
Why?
|
|
Huang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|